Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data

Background: Double blockade with pertuzumab and trastuzumab combined with chemotherapy is the standard neoadjuvant treatment for HER2-positive early breast cancer. Data derived from clinical trials indicates that the response rates differ among intrinsic subtypes of breast cancer. The aim of this st...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Front Oncol
Päätekijät: Díaz-Redondo, Tamara, Lavado-Valenzuela, Rocio, Jimenez, Begoña, Pascual, Tomas, Gálvez, Fernando, Falcón, Alejandro, Alamo, Maria del Carmen, Morales, Cristina, Amerigo, Marta, Pascual, Javier, Sanchez-Muñoz, Alfonso, González-Guerrero, Macarena, Vicioso, Luis, Laborda, Aurora, Ortega, Maria Victoria, Perez, Lidia, Fernandez-Martinez, Aranzazu, Chic, Nuria, Jerez, Jose Manuel, Alvarez, Martina, Prat, Aleix, Ribelles, Nuria, Alba, Emilio
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Frontiers Media S.A. 2019
Aiheet:
Oncology
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6848376/
https://ncbi.nlm.nih.gov/pubmed/31750258
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.01178
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia